Heterozygous germline ATM mutations do not contribute to radiation- associated malignancies after Hodgkin's disease

Journal of Clinical Oncology

Volumn 17, Issue 4, 1999, Pages 1259-1266

  Nichols, Kim E ^a   Levitz, Seth ^a   Shannon, Kristen E ^a   Wahrer, Doke C R ^a   Bell, Daphne W ^a   Chang, Gloria ^a   Hegde, Sanjay ^a   Neuberg, Donna ^a   Shafman, Timothy ^a   Tarbell, Nancy J ^a   Mauch, Peter ^a   Ishioka, Chikashi ^a   Haber, Daniel A ^a   Diller, Lisa ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; ATAXIA TELANGIECTASIA; BREAST CANCER; CANCER RADIOTHERAPY; CANCER RISK; CHILD; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC RISK; HETEROZYGOSITY; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; RADIATION CARCINOGENESIS; SECOND CANCER; SKIN CANCER;

EID: 0032906165     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.4.1259     Document Type: Article

References (68)

1. Aisenberg AC, Finkelstein DM, Doppke KP, et al: High risk of breast carcinoma after irradiation of young women with Hodgkin's disease. Cancer 79:1203-1210, 1997
2. Bhatia S, Robison L, Oberlin O, et al: Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 334:745-751, 1996
3. Carey RW, Lingood RM, Wood W, et al: Breast cancer developing in four women cured of Hodgkin's disease. Cancer 54:2234-2236, 1984
4. Donaldson SS, Hancock SL: Second cancers after Hodgkin's disease in childhood. N Engl J Med 334:792-794, 1996
5. Doria R, Holford T, Farber LR, et al: Second solid malignancies after combined modality therapy for Hodgkin's disease. J Clin Oncol 13:2016-2022, 1995
6. Hancock SL, Tucker MA, Hoppe RT: Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst 85:25-31, 1993
7. Mauch PM, Kalish LA, Marcus KC, et al: Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: Long-term analysis of risk factors and outcome. Blood 87:3625-3632, 1996
8. Tarbell NJ, Gelber RD, Weinstein HJ, et al: Sex differences in risk of second malignant tumors after Hodgkin's disease in childhood. Lancet 341:1428-1432, 1993
9. Vlachaki MT, Ha CS, Hagemeister FB, et al: Long-term outcome of treatment for Ann Arbor stage 1 Hodgkin's disease: Patterns of failure, late toxicity and second malignancies. Int J Radiat Oncol Biol Physiol 39:609-616, 1997
10. Wolden SL, Lamborn KR, Cleary SF, et al: Second cancers following pediatric Hodgkin's disease. J Clin Oncol 16:536-544, 1998
11. Yahalom J, Petrek JA, Biddinger PW, et al: Breast cancer in patients irradiated for Hodgkin's disease: A clinical and pathologic analysis of 45 events in 37 patients. J Clin Oncol 10:1674-1681, 1992
12. Coleman C, Williams C, Flint A, et al: Hematologic neoplasia in patients treated for Hodgkin's disease. N Engl J Med 297:1249-1252, 1977
13. Valagussa P, Santoro A, Fossati-Bellani F, et al: Second acute leukemia and other malignancies following treatment for Hodgkin's disease. J Clin Oncol 4:830-837, 1986
14. Travis LB, Curtis RE, Glimelius B, et al: Second cancers among long-term survivors of non-Hodgkin's lymphoma. J Natl Cancer Inst 85:1932-1937, 1993
15. Hudson MM, Jones D, Boyette J, et al: Late mortality of long-term survivors of childhood cancer. J Clin Oncol 15:2205-2213, 1997
16. Mauch P, Kalish L, Marcus K, et al: Long-term survival in Hodgkin's disease. Cancer J Sci Am 1:33-42, 1995
17. Hoppe R: Hodgkin's disease: Complications of therapy and excess mortality. Ann Oncol 8:115-118, 1997
18. Swift M, Morrell D, Cromartie E, et al: The incidence and gene frequency of ataxia-telangiectasia in the U.S. Am J Hum Genet 39:573-583, 1986
19. Savitsky K, Bar-Shira A, Gilad S, et al: A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 268:1749-1753, 1995
20. Borresen A-L, Andersen TI, Tretli S, et al: Breast cancer and other cancers in Norwegian families with ataxia-telangiectasia. Genes Chromosomes Cancer 2:339-340, 1990
21. Easton DF: Cancer risk in A-T heterozygotes. Int J Radiat Biol 66:S177-S182, 1994 (suppl)
22. Morrell D, Cromartie E, Swift M: Mortality and cancer incidence in 263 patients with ataxia-telangiectasia. J Natl Cancer Inst 77:89-92, 1986
23. Morrell D, Chase CL, Swift M: Cancers in 44 families with ataxia-telangiectasia. N Engl J Med 325:1831-1836, 1990
24. Pippard EC, Hall AJ, Barker DJ, et al: Cancer in homozygotes and heterozygotes of ataxia-telangiectasia and xeroderma pigmentosum in Britain. Cancer Res 48:2929-2932, 1988
25. Swift M, Sholman L, Perry M, et al: Malignant neoplasms in the families of patients with ataxia-telangiectasia. Cancer Res 35:209-215, 1976
26. Swift M, Reitnauer PJ, Morrell D, et al: Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med 316:1289-1294, 1987
27. Swift M, Morrell D, Massey RB, et al: Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 325:1381-1386, 1991
28. Taylor AMR, Metcalfe JA, Thick J, et al: Leukemia and lymphoma in ataxia telangiectasia. Blood 87:423-438, 1996
29. Metcalfe JA, Parkhill J, Campbell L, et al: Accelerated telomere shortening in ataxia telangiectasia. Nat Genet 13:350-353, 1996
30. Thacker J: Cellular radiosensitivity in ataxia-telangiectasia. Int J Radiat Biol 66:S87-S96, 1994 (suppl)
31. Scott D, Spreadborough AR, Roberts SA: Radiation-induced G2 delay and spontaneous chromosome aberrations in ataxia-telangiectasia homozygotes and heterozygotes. Int J Radiat Biol 66:S157-S163, 1994 (suppl)
32. Smilenov LB, Morgan SE, Mellado W, et al: Influence of ATM function on telomere metabolism. Oncogene 15:2659-2665, 1997
33. Artuso M, Esteve A, Bresil H, et al: The role of the ataxia telangiectasia gene in the p53, WAF1/CIP(p21) and GADD45-mediated response to DNA damage produced by ionising radiation. Oncogene 11:1427-1435, 1995
34. Baskaran R, Wood LD, Whitaker LL, et al: Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation. Nature 387:516-519, 1997
35. Jung M, Lee SA, Zhang Y, et al: Regulation of p53 in response to ionizing radiation in ataxia telangiectasia fibroblasts. Int J Radiat Oncol Biol Physiol 37:417-422, 1997
36. Khanna KK, Beamish H, Yan J, et al: Nature of G1/S cell cycle checkpoint defect in ataxia-telangiectasia. Oncogene 11:609-618, 1995
37. Lavin MF, Khanna KK, Beamish H, et al: Defect in radiation signal transduction in ataxia-telangiectasia. Int J Radiat Biol 66:S151-S156, 1994 (suppl)
38. Meyn MS, Strasfeld L, Allen C: Testing the role of p53 in the expression of genetic instability and apoptosis in ataxia telangiectasia. Int J Radiat Biol 66:8141-5149, 1994
39. Westphal CH, Rowan S, Schmaltz C, et al: atm and p53 cooperate in apoptosis and suppression of tumorigenesis, but not in resistance to radiation toxicity. Nat Genet 16:397-401, 1997
40. Xie G, Habbersett RC, Jia Y, et al: Requirements for p53 and the ATM gene product in the regulation of G1/S and S phase checkpoints. Oncogene 16:721-736, 1998
41. Xu Y, Baltimore D: Dual roles of ATM in the cellular response to radiation and in cell growth control. Genes Dev 10:2401-2410, 1996
42. FitzGerald MG, Bean JM, Hegde SR, et al: Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat Genet 15:307-310, 1997
43. West CM, Elyan SA, Berry P, et al: A comparison of the radiosensitivity of lymphocytes from normal donors, cancer patients, individuals with ataxia telangiectasia (A-T) and A-T heterozygotes. Int J Radiat Biol 68:197-203, 1995
44. Athma P, Rappaport R, Swift M: Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet Cytogenet 92:130-134, 1996
45. Anderson MA, Gusella JF: Use of cyclosporin A in establishing Epstein-Barr virus-transformed human lymphoblastoid cell lines. In Vitro 20:856-858, 1984
46. Ishioka C, Suzuki T, FitzGerald M, et al: Detection of truncating mutations in the BRCA1 and APC genes using a rapid screening assay in yeast. Proc Natl Acad Sci USA 94:2449-2453, 1997
47. Diehl V, Tesch H: Hodgkin's disease: Environmental or genetic? N Engl J Med 332:461-462, 1995
48. Ferraris AM, Racchi O, Rapezzi D, et al: Familial Hodgkin's disease: A disease of young adulthood? Ann Hematol 74:131-134, 1997
49. Mack TM, Cozen W, Shibata DK, et al: Concordance for Hodgkin's disease in identical twins suggesting genetic susceptibility to the young-adult form of the disease. N Engl J Med 332:413-418, 1995
50. Byrd PJ, McConville CM, Cooper P, et al: Mutations revealed by sequencing the 5′ half of the gene for ataxia telangiectasia. Hum Mol Genet 5:145-149, 1996
51. Gilad S, Khosravi R, Shkedy D, et al: Predominance of null mutations in ataxia telangiectasia. Hum Mol Genet 5:433-439, 1996
52. Gilad S, Khosravi R, Harnik R, et al: Identification of ATM mutations using extended RT-PCR and restriction endonuclease fingerprinting, and elucidation of the repertoire of A-T mutations in Israel. Hum Mutat 11:69-75, 1998
53. Stankovic T, Kidd AMJ, Sutcliffe A, et al: ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: Expression of mutant ATM and the risk of leukemia, lymphoma and breast cancer. Am J Hum Genet 62:334-345, 1998
54. Telatar M, Wang Z, Udar N, et al: Ataxia-telangiectasia: Mutations in ATM cDNA detected by protein-truncation screening. Am J Hum Genet 59:40-44, 1996
55. Vorechovsky I, Luo L, Lindblom A, et al: ATM mutations in cancer families. Cancer Res 56:4130-4133, 1996
56. Wright J, Teraoka S, Onengut S, et al: A high frequency of distinct ATM gene mutations in ataxia-telangiectasia. Am J Hum Genet 59:839-846, 1996
57. Land CE, Tokunaga M, Tokuoka S, et al: Early-onset breast cancer in A-bomb survivors. Lancet 342:237, 1993
58. Tokunaga M, Land CE, Tokuota S, et al: Incidence of female breast cancer among atomic bomb survivors, 1950-1985. Radiat Res 138:209-223, 1994
59. Boice J, Mandel J, Doody M: Breast cancer among radiologie technologists. JAMA 274:394-401, 1995
60. Gross PE, Sierra S: Current perspectives on radiation-induced breast cancer. J Clin Oncol 16:338-347, 1998
61. Shapiro CL, Mauch PM: Radiation-associated breast cancer after Hodgkin's disease: Risks and screening in perspective. J Clin Oncol 10:1662-1665, 1992
62. Kony SJ, de Vathaire F, Chompret A, et al: Radiation and genetic factors in the risk of second malignant neoplasms after a first cancer in childhood. Lancet 350:91-95, 1997
63. Draper GJ, Sanders BM, Kingston JE: Second primary neoplasms in patients with retinoblastoma. Br J Cancer 53:661-671, 1986
64. Eng C, Li FP, Abramson DH, et al: Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst 85:1121-1128, 1993
65. Hisada M, Garber JE, Fung CY, et al: Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst 90:606-611, 1998
66. Malkin D, Jolly KW, Barbier N, et al: Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. N Engl J Med 326:1309-1315, 1992
67. Strong LC, Williams WR, Tainsky MA: The Li-Fraumeni syndrome: From clinical epidemiology to molecular genetics. Am J Epidemiol 135:190-199, 1992
68. Strong LC, Stine M, Norsted TL: Cancer in survivors of childhood soft tissue sarcoma and their relatives. J Natl Cancer Inst 79:1213-1220, 1987